|
| 37355546 | Flow Cytometry Identification of Cell Compartments in the Murine Brain. | Methods Mol Biol | 2023 |
| 37557181 | Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer. | Cell Chem Biol | 2023 |
| 37316586 | Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas. | Neuroradiology | 2023 |
| 37124503 | BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience. | Front Oncol | 2023 |
| 37355546 | Flow Cytometry Identification of Cell Compartments in the Murine Brain. | Methods Mol Biol | 2023 |
| 37557181 | Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer. | Cell Chem Biol | 2023 |
| 37124503 | BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience. | Front Oncol | 2023 |
| 37316586 | Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas. | Neuroradiology | 2023 |
| 35000262 | In vivo genome-editing screen identifies tumor suppressor genes that cooperate with Trp53 loss during mammary tumorigenesis. | Mol Oncol | 2022 |
| 36355260 | Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature. | J Neurooncol | 2022 |
| 35728397 | Adult medulloblastoma in an Australian population. | J Clin Neurosci | 2022 |
| 36122487 | How has the COVID-19 pandemic impacted clinical care and research in Neuro-Oncology? | J Clin Neurosci | 2022 |
| 35187951 | PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer. | Future Oncol | 2022 |
| 35000262 | In vivo genome-editing screen identifies tumor suppressor genes that cooperate with Trp53 loss during mammary tumorigenesis. | Mol Oncol | 2022 |
| 35728397 | Adult medulloblastoma in an Australian population. | J Clin Neurosci | 2022 |
| 36355260 | Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature. | J Neurooncol | 2022 |
| 36122487 | How has the COVID-19 pandemic impacted clinical care and research in Neuro-Oncology? | J Clin Neurosci | 2022 |
| 35187951 | PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer. | Future Oncol | 2022 |
| 34119258 | Perioperative clinical trials for glioma: Raising the bar. | J Clin Neurosci | 2021 |
| 34119258 | Perioperative clinical trials for glioma: Raising the bar. | J Clin Neurosci | 2021 |
| 33496801 | A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours. | Cancer Chemother Pharmacol | 2021 |
| 34412718 | Medical Assistance in Dying (MAiD) in Brain Cancer: Whose Autonomy Are We Respecting? | Can J Neurol Sci | 2021 |
| 33496801 | A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours. | Cancer Chemother Pharmacol | 2021 |
| 34412718 | Medical Assistance in Dying (MAiD) in Brain Cancer: Whose Autonomy Are We Respecting? | Can J Neurol Sci | 2021 |
| 31589320 | Modeling Breast Cancer Using CRISPR-Cas9-Mediated Engineering of Human Breast Organoids. | J Natl Cancer Inst | 2020 |
| 31589320 | Modeling Breast Cancer Using CRISPR-Cas9-Mediated Engineering of Human Breast Organoids. | J Natl Cancer Inst | 2020 |
| 32245900 | Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer. | Clin Cancer Res | 2020 |
| 32341449 | Targeting triple-negative breast cancers with the Smac-mimetic birinapant. | Cell Death Differ | 2020 |
| 32220419 | Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care. | Gynecol Oncol | 2020 |
| 32245900 | Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer. | Clin Cancer Res | 2020 |
| 32341449 | Targeting triple-negative breast cancers with the Smac-mimetic birinapant. | Cell Death Differ | 2020 |
| 32220419 | Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care. | Gynecol Oncol | 2020 |
| 30518523 | A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. | Cancer Discov | 2019 |
| 30518523 | A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. | Cancer Discov | 2019 |
| 29083093 | Precision oncology using a clinician-directed, tailored approach to molecular profiling. | Asia Pac J Clin Oncol | 2018 |
| 29766337 | A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. | Invest New Drugs | 2018 |
| 29083093 | Precision oncology using a clinician-directed, tailored approach to molecular profiling. | Asia Pac J Clin Oncol | 2018 |
| 29766337 | A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. | Invest New Drugs | 2018 |
| 28768804 | Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. | Sci Transl Med | 2017 |
| 28768804 | Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. | Sci Transl Med | 2017 |
| 27453470 | Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. | Cell | 2016 |
| 27453470 | Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. | Cell | 2016 |
| 26315107 | Use of vemurafenib in a patient unable to swallow whole. | J Oncol Pharm Pract | 2016 |
| 26315107 | Use of vemurafenib in a patient unable to swallow whole. | J Oncol Pharm Pract | 2016 |
| 25537232 | Histone deacetylase inhibitors in cancer: what have we learned? | Cancer | 2015 |
| 25537232 | Histone deacetylase inhibitors in cancer: what have we learned? | Cancer | 2015 |
| 25849559 | Patient-derived xenograft models of breast cancer and their predictive power. | Breast Cancer Res | 2015 |
| 26078272 | H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. | J Immunol | 2015 |
| 26279503 | First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. | J Clin Neurosci | 2015 |
| 26279189 | Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. | Cell | 2015 |